ArticleCancer2025

INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Cristina Papayannidis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.